Together, these studies strongly suggest that APOC3 inhibition could be effective in treating hypertriglyceridemia and preventing atherosclerotic CVD, especially in conditions in which APOC3 levels are increased. This evidence concerns the gene APOC3 and hypertriglyceridemia.